Jeremy Grantham's FOLD Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 941,266 shares of Amicus Therapeutics, Inc. (FOLD) worth $13.61 M, representing 0.03% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Jeremy Grantham has initiated a new position in FOLD, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Amicus Therapeutics (FOLD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amicus Therapeutics (FOLD) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +941,266 | New Buy | 941,266 | $14.46 |
Jeremy Grantham's Amicus Therapeutics Investment FAQs
Jeremy Grantham first purchased Amicus Therapeutics, Inc. (FOLD) in Q1 2026, acquiring 941,266 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Amicus Therapeutics, Inc. (FOLD) for 1 quarters since Q1 2026.
Jeremy Grantham's largest addition to Amicus Therapeutics, Inc. (FOLD) was in Q1 2026, adding 941,266 shares worth $13.61 M.
According to the latest 13F filing for Q1 2026, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 941,266 shares of Amicus Therapeutics, Inc. (FOLD), valued at approximately $13.61 M.
As of the Q1 2026 filing, Amicus Therapeutics, Inc. (FOLD) represents approximately 0.03% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Amicus Therapeutics, Inc. (FOLD) was 941,266 shares, as reported at the end of Q1 2026.